LLY

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Eli Lilly and Company, IND, NYSE, LXR, DSM-IV codes, Obesity, LLY, MD, Doctor of Philosophy, Agonal respiration, Commercialization, NASH, Cancer, ACMSD, Series, Patient, Pharmaceutical industry, Nursing, Saṃsāra

The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.

Key Points: 
  • The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.
  • OrsoBio will utilize the Series A funding to advance the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
  • ACMSD inhibitor (aminocarboxymuconate semialdehyde decarboxylase inhibitor): Selection of a development candidate for potential treatment of metabolic and inflammatory liver and kidney disorders and advancement of IND-enabling activities.
  • “We are grateful for the continued trust in our team and commitment to our mission to improve clinical outcomes in patients with obesity and associated metabolic disorders.

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Eli Lilly and Company, Experiment, NYSE, Reversibility, Prior, SLL, Use, LLY, Safety, Chronic lymphocytic leukemia, Mantle cell lymphoma, Covalent bond, Medication discontinuation, Society, ASH, Lymphocytosis, Tyrosine kinase, CLL, Poster, MCL, Lymphoid leukemia, Therapy, BTK, Manchester Grand Hyatt Hotel, Pharmaceutical industry, Vaccine, Hotel, Patient

INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.

Key Points: 
  • INDIANAPOLIS, Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
  • The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.
  • In mantle cell lymphoma (MCL), an oral presentation will provide updated safety and efficacy results of pirtobrutinib in all patients, including those with biologically high-risk relapsed or refractory MCL.
  • Additionally, poster presentations will provide data on the clinical impact of pirtobrutinib following cBTKi treatment across other B-cell malignancies.

Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Disney Channel Hits: Take 2, Lilly, Eli Lilly and Company, Boehringer Ingelheim, Dean (education), NYSE, EGFR, UC, Human, Kidney, LLY, Diabetes, Inclusion, Glomerular filtration rate, HIV disease progression rates, UACR, FAAFP, Chronic kidney disease, Risk, University of California, Irvine School of Medicine, Kidney disease, Blood, Diversity, CKD, It Takes Two, Patient, Diagnosis, Heart failure, Head, Pharmaceutical industry, Nursing, Medicine, F.A.C.E

More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.

Key Points: 
  • More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.
  • By turning "It Takes Two" into "It Takes 2 – The Remix," he is helping Boehringer Ingelheim and Lilly reach key audiences to spotlight the significance of complete testing.
  • It Takes 2 encourages healthcare professionals to add UACR testing to screen for CKD, as eGFR testing only tells half the story.
  • By tapping into a powerful combination of nostalgia and memorability, It Takes 2 is helping bring greater recognition to kidney disease."

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Thursday, October 26, 2023
Janus, Patient, FDA, Crohn's & Colitis Foundation, Eli Lilly and Company, Headache, Icahn School of Medicine at Mount Sinai, NYSE, Food, Lower respiratory tract infection, UC, UC-2, Hope, LLY, NRS, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Jaki, Ulcerative colitis, Rash, UC-1, Mount Sinai, Hepatotoxicity, Arthralgia, Immunology, Tuberculosis, European, Pharmaceutical industry, Lilly, Gastroenterology, Medicine

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Key Points: 
  • "Today's approval represents a novel scientific advancement, providing a treatment that may offer relief from three key symptoms—stool frequency, rectal bleeding and bowel urgency—regardless of past biologic use."
  • All patients in the LUCENT program had past treatments, including biologic treatments, that did not work, stopped working or that they could not tolerate.
  • Patients in steroid-free clinical remission were steroid-free for at least three months prior to the end of the 52-week assessment.
  • "Bowel urgency is one of the most disruptive symptoms for patients with ulcerative colitis," said Michael Osso, president and chief executive officer, Crohn's & Colitis Foundation.

Lilly to Participate in UBS Biopharma Conference 2023

Retrieved on: 
Thursday, October 26, 2023
LLY, Eli Lilly and Company, Conference, NYSE, Pharmaceutical industry, Broadcasting

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023.

Key Points: 
  • INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023.
  • Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.

Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement

Retrieved on: 
Friday, October 20, 2023
Lilly, Eli Lilly and Company, NYSE, LLY, Pharmaceutical industry

INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023.

Key Points: 
  • INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023.
  • Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.

POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT

Retrieved on: 
Friday, October 6, 2023
Class Action Lawsuit, Professional Services, Legal, Eli Lilly and Company, LLY, NYSE, KSF, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of POINT Biopharma Global, Inc. (NasdaqCM: PNT) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of POINT Biopharma Global, Inc. (NasdaqCM: PNT) to Eli Lilly and Company (NYSE: LLY).
  • Under the terms of the proposed transaction, shareholders of POINT will receive $12.50 in cash for each share of POINT that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

Lilly Announces Details of Presentations at ESMO Congress 2023

Retrieved on: 
Friday, October 6, 2023
Congress, Selpercatinib, Eli Lilly and Company, ID, NYSE, NSCLC, RET, Risk, Adjuvant, MTC, Lilly, The Monarch School, Triple-negative breast cancer, Recurrence, Everolimus, CEST, Oncology, ESMO, LLY, EMBER, EBC, Transfection, ET, Vandetanib, European Society for Medical Oncology, Patient, Poster, Cabozantinib, Pharmaceutical industry, Vaccine

In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.

Key Points: 
  • In a late-breaking oral presentation, Lilly will share five-year results, an established benchmark for adjuvant breast cancer trials, from a preplanned interim analysis of the Phase 3 monarchE study.
  • A separate poster presentation will provide data on the impact of dose reductions on efficacy for patients treated in monarchE.
  • In two late-breaking oral presentations that will be featured as part of the Presidential Symposium 1 on Saturday, October 21, Lilly will share interim analysis results from the Phase 3 LIBRETTO-431 and LIBRETTO-531 clinical studies.
  • In a mini oral presentation, Lilly will share clinical data on imlunestrant as a single agent and in combination therapy.